359 related articles for article (PubMed ID: 24476390)
21. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
Spagnolo P; Maher TM; Richeldi L
Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
[TBL] [Abstract][Full Text] [Related]
23. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
[TBL] [Abstract][Full Text] [Related]
24. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
25. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
George PM; Wells AU
Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.
Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU
Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023
[TBL] [Abstract][Full Text] [Related]
27. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Anderson A; Shifren A; Nathan SD
Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012
[TBL] [Abstract][Full Text] [Related]
28. Pirfenidone in idiopathic pulmonary fibrosis.
Maher TM
Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
[TBL] [Abstract][Full Text] [Related]
29. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.
Nathan SD; du Bois RM; Albera C; Bradford WZ; Costabel U; Kartashov A; Noble PW; Sahn SA; Valeyre D; Weycker D; King TE
Respir Med; 2015 Jul; 109(7):914-22. PubMed ID: 25956020
[TBL] [Abstract][Full Text] [Related]
30. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
[TBL] [Abstract][Full Text] [Related]
31. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Xaubet A; Serrano-Mollar A; Ancochea J
Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
[TBL] [Abstract][Full Text] [Related]
32. Pirfenidone for idiopathic pulmonary fibrosis.
Bouros D
Lancet; 2011 May; 377(9779):1727-9. PubMed ID: 21571363
[No Abstract] [Full Text] [Related]
33. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.
Kreuter M; Bonella F; Maher TM; Costabel U; Spagnolo P; Weycker D; Kirchgaessler KU; Kolb M
Thorax; 2017 Feb; 72(2):148-153. PubMed ID: 27708114
[TBL] [Abstract][Full Text] [Related]
34. [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis].
Bonella F; Wessendorf TE; Costabel U
Dtsch Med Wochenschr; 2013 Mar; 138(11):518-23. PubMed ID: 23423955
[TBL] [Abstract][Full Text] [Related]
35. Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Aravena C; Labarca G; Venegas C; Arenas A; Rada G
PLoS One; 2015; 10(8):e0136160. PubMed ID: 26308723
[TBL] [Abstract][Full Text] [Related]
36. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis.
Ley B; Bradford WZ; Weycker D; Vittinghoff E; du Bois RM; Collard HR
Eur Respir J; 2015 May; 45(5):1374-81. PubMed ID: 25614172
[TBL] [Abstract][Full Text] [Related]
37. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
Potts J; Yogaratnam D
Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
[TBL] [Abstract][Full Text] [Related]
38. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis.
Richeldi L
Eur Respir Rev; 2012 Jun; 21(124):147-51. PubMed ID: 22654087
[TBL] [Abstract][Full Text] [Related]
39. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
King TE; Brown KK; Raghu G; du Bois RM; Lynch DA; Martinez F; Valeyre D; Leconte I; Morganti A; Roux S; Behr J
Am J Respir Crit Care Med; 2011 Jul; 184(1):92-9. PubMed ID: 21474646
[TBL] [Abstract][Full Text] [Related]
40. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.
Kim ES; Keating GM
Drugs; 2015 Feb; 75(2):219-30. PubMed ID: 25604027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
